Updated 04:19 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,873.60 -0.33% CL 88.49 -0.08% BTC 64,896.46 +1.20%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,874 −0.33% BTC $64,896 +1.20% VIX 19.30 +3.21% latest tape · as of 04:19 UTC
The Screen · Consumer Cyclical

Baozun Inc.

BZUN · Nasdaq · USD · Market cap $143M

FAIL · Does not pass the screen
3.49 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price3.49 USD at the 13 Nov 2026 close
  • Fair value6.93. Our model only; no analyst estimate to cross-check.
  • Our value readUndervalued vs our fair value, as of 13 Nov 2026
  • Our regime readMarkdown, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $6.33 to $6.98, base estimate $6.93 (screen dated 2026-11-13).

Current read
Markdown ?
Undervalued · screened 2026-11-13
  • Trend Markdown
  • Insiders insiders bought, latest filing 2026-10-21
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price3.49 USD
Fair value6.93Our model only; no analyst estimate to cross-check.
Value readUndervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-10-21Read Markup3.67-4.9% to today Accumulation gives way to Markup after a 25% rise in 3 weeks
2026-10-02Read Accumulation2.93+19.1% to today ✓Markup gives way to Accumulation after an 11% rise in 6 weeks
2026-08-24Read Markup2.65+31.7% to today ✓Markdown gives way to Markup
2026-07-02Read Markdown2.65+31.7% to today First review on file: Markdown

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markdown label.

Baozun Inc. holds its Markdown at $3.49. Consolidating, no directional conviction, held for 1 days.

As held on the ledger · 2026-11-13
PhaseMarkdown · caution
Quantitative stateConsolidating, no directional conviction, held for 1 days
Price at the screen$3.49
Valuation0.00 trailing · 4.21 forward price to earnings
Values screenFAIL
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 1,354.64% Below 33% Interest-bearing debt is 1,354.6% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 1,856.25% Below 33% Interest-bearing cash and securities are 1,856.3% of assets, above the one-third limit. Fail
Receivables 0.00% Below 49% Money owed to the company is 0.0% of assets, under the 49% limit. Pass
Revenue purity 0.59% Below 5% Only 0.6% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Baozun's business is in a permissible area, but its interest-bearing debt is about 1355% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when BZUN's ethical verdict changes

Today BZUN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our model only; no analyst estimate to cross-check.

Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 50% discount to our $6.93 fair value, weak competitive moat, 5.90% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

6.33Conservative6.93Base case6.98Growth case 3.49Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 49.6% discount to the base estimate.

Price History & Projections

Where our models see it going: fair-value estimate $6.93, with a range of $6.33 to $6.98, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it stands out

A 6%-growth business trading at just 4.2x forward earnings, with a weak competitive moat and minimal debt. That is a 50% discount to our $6.93 fair value: the market is pricing it cautiously while the fundamentals argue otherwise.

The fundamentals · plain-English read
Forward P/E4.2xcheap for a company growing this fast
Trailing P/E0.0x
EPS, trailing-0.62
EPS, forward0.70
Revenue growth+5.9%slow but positive growth
Profit margin-2.4%currently unprofitable
Return on equity-3.5%not currently earning a positive return on equity
Debt to equity0.35minimal debt: a conservative balance sheet
MoatWEAK
Market cap$143M

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

BZUN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-13 Markup $3.48 +6.4% Entry 10

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 23% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (7 analysts) rates it buy, with a mean price target of $4.

2026-11-02 Markup $3.27 -10.9% Entry 9

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 10.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (7 analysts) rates it buy, with a mean price target of $4.

2026-10-21 Markup · changed $3.67 +10.9% Entry 8

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (7 analysts) rates it buy, with a mean price target of $4.

2026-10-14 Accumulation $3.31 +13.0% Entry 7

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 13.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (7 analysts) rates it buy, with a mean price target of $4.

2026-10-02 Accumulation · changed $2.93 +10.6% Entry 6

The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 10.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (7 analysts) rates it buy, with a mean price target of $4.

2026-08-24 Markup · changed $2.65 +0.0% Entry 5

The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (7 analysts) rates it buy, with a mean price target of $4.

2026-07-24 Markdown $2.65 +0.0% Entry 4

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (7 analysts) rates it buy, with a mean price target of $4.

2026-07-18 Markdown $2.65 +0.0% Entry 3

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (7 analysts) rates it buy, with a mean price target of $4.

2026-07-03 Markdown $2.65 +0.0% Entry 2

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.

2026-07-02 Markdown $2.65 Entry 1

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · BZUN
DateInsiderTitleTypeSharesValue
2026-10-21 Qiu Wenbin CEO P - Purchase 11,400 $39,900
2026-09-18 Qiu Wenbin CEO P - Purchase 13,900 $39,825
2026-04-17 QIU WENBIN VINCENT Chief Executive Officer 16,000 $50,240
2026-04-14 QIU WENBIN VINCENT Chief Executive Officer 23,600 $60,253
2026-04-13 WU JUNHUA Officer and Director 16,456 $40,492
2026-04-10 QIU WENBIN VINCENT Chief Executive Officer 24,050 $60,189
2026-04-08 QIU WENBIN VINCENT Chief Executive Officer 23,600 $60,048
2026-04-08 WU JUNHUA Officer and Director 30,886 $78,450
2026-04-02 WU JUNHUA Officer and Director 30,000 $74,019
2026-03-31 WU JUNHUA Officer and Director 14,000 $33,597

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $2.70 -3.3% · $967 -3.3%
2 months $2.42 +7.9% · $1,079 +7.9%
3 months $2.41 +8.3% · $1,083 +8.3%
6 months $2.79 -6.5% · $936 -6.5%
1 year $2.77 -5.8% · $942 -5.8%
2 years $2.55 +2.4% · $1,024 +2.4%
3 years $4.23 -38.3% · $617 -38.3%
5 years $37.05 -93.0% · $70 -93.0%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever BZUN does next, these words stay.

Baozun Inc. · BZUN · Markdown · $3.49
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.